Bio-AMD Inc. (fka BIAD)

[derkampfer]

Based on recent 10-Q filed "The Partner has prospectively agreed to fund a Phase 2 development of our MIDS" This means more payments may be forthcoming after Phase 1 payments end end of Q1 2017 (March)

Current cost reduction measures by Tom Barr allow slower operations burn and within budget restrictions of phase 1 payments.

Thank you Tom for cutting costs and not diluting shareholders.

Only takes one interested Partner in COAG and this is back to $.07-$.10. More depending on nature of deal.

Good luck patient longs

DK